Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Erfonrilimab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 22 Aug 2023 Status changed from recruiting to discontinued. Data collected did not support the study endpoints
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 23 Nov 2021 Status changed from not yet recruiting to recruiting.